ALK-driven tumors and targeted therapy: focus on crizotinib

References

• HanahanDWeinbergRAHallmarks of cancer: the next generationCell2011144564667421376230
   PubMed Web of Science ®Google Scholar
• MorrisSWKirsteinMNValentineMBFusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphomaScience19942635151128112848122112
   PubMed Web of Science ®Google Scholar
• FaliniBAnaplastic large cell lymphoma: pathological, molecular and clinical featuresBr J Haematol2001114474176011564061
   PubMed Web of Science ®Google Scholar
• ManoHALKoma: a cancer subtype with a shared targetCancer Discov20122649550222614325
   PubMed Web of Science ®Google Scholar
• ChristensenJGZouHYArangoMECytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphomaMol Cancer Thera2007612 Pt 133143322
   PubMed Web of Science ®Google Scholar
• SteinHMasonDYGerdesJThe expression of the Hodgkin’s disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cellsBlood19856648488583876124
   PubMed Web of Science ®Google Scholar
• MorganRHechtBKSandbergAAHechtFSmithSDChromosome 5q35 breakpoint in malignant histiocytosisN Engl J Med19863142013223702936
   PubMed Web of Science ®Google Scholar
• MasonDYBastardCRimokhRCD30-positive large cell lymphomas (‘Ki-1 lymphoma’) are associated with a chromosomal translocation involving 5q35Br J Haematol19907421611682156548
   PubMed Web of Science ®Google Scholar
• LoweEJLimMSPotential therapies for anaplastic lymphoma kinase-driven tumors in children: progress to datePaediatr Drugs201315316316923696342
   PubMed Web of Science ®Google Scholar
• FerreriAJGoviSPileriSASavageKJAnaplastic large cell lymphoma, ALK-positiveCrit Rev Oncol Hematol201283229330222440390
   PubMed Web of Science ®Google Scholar
• SavageKJHarrisNLVoseJMInternational Peripheral T-Cell Lymphoma ProjectALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma ProjectBlood2008111125496550418385450
   PubMed Web of Science ®Google Scholar
• ZamoAChiarleRPivaRAnaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell deathOncogene20022171038104711850821
   PubMed Web of Science ®Google Scholar
• ZhangQRaghunathPNXueLMultilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphomaJ Immunol2002168146647411751994
   PubMed Web of Science ®Google Scholar
• AminHMMcDonnellTJMaYSelective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphomaOncogene200423325426543415184887
   PubMed Web of Science ®Google Scholar
• ChiarleRSimmonsWJCaiHStat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic targetNat Med200511662362915895073
   PubMed Web of Science ®Google Scholar
• KhouryJDRassidakisGZMedeirosLJAminHMLaiRMethylation of SHP1 gene and loss of SHP1 protein expression are frequent in systemic anaplastic large cell lymphomaBlood200410451580158115317731
   PubMed Web of Science ®Google Scholar
• ZhangQWangHYMarzecMRaghunathPNNagasawaTWasikMASTAT3- and DNA methyltransferase 1-mediated epigenetic silencing of SHP-1 tyrosine phosphatase tumor suppressor gene in malignant T lymphocytesProc Natl Acad Sci U S A2005102196948695315870198
   PubMed Web of Science ®Google Scholar
• AminHMMedeirosLJMaYInhibition of JAK3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphomaOncogene200322355399540712934099
   PubMed Web of Science ®Google Scholar
• QiuLLaiRLinQAutocrine release of interleukin-9 promotes Jak3-dependent survival of ALK+ anaplastic large-cell lymphoma cellsBlood200610872407241516763206
   PubMed Web of Science ®Google Scholar
• BardJDGelebartPAnandMAminHMLaiRAberrant expression of IL-22 receptor 1 and autocrine IL-22 stimulation contribute to tumorigenicity in ALK+ anaplastic large cell lymphomaLeukemia20082281595160318509351
   PubMed Web of Science ®Google Scholar
• AnandMLaiRGelebartPβ-catenin is constitutively active and increases STAT3 expression/activation in anaplastic lymphoma kinase-positive anaplastic large cell lymphomaHaematologica201196225326120971814
   PubMed Web of Science ®Google Scholar
• McDonnellSRHwangSRBasrurVNPM-ALK signals through glycogen synthase kinase 3β to promote oncogenesisOncogene201231323733374022179823
   PubMed Web of Science ®Google Scholar
• McDonnellSRHwangSRRollandDIntegrated phosphoproteomic and metabolomic profiling reveals NPM-ALK-mediated phosphorylation of PKM2 and metabolic reprogramming in anaplastic large cell lymphomaBlood2013122695896823814019
   PubMed Web of Science ®Google Scholar
• WarburgOWindFNegeleinEThe metabolism of tumors in the bodyJ Gen Physiol19278651953019872213
   PubMedGoogle Scholar
• LimMSCarlsonMLCrockettDKThe proteomic signature of NPM/ALK reveals deregulation of multiple cellular pathwaysBlood200911481585159519531656
   PubMed Web of Science ®Google Scholar
• LagarrigueFDupuis-CoronasSRamelDMatrix metalloproteinase-9 is upregulated in nucleophosmin-anaplastic lymphoma kinase-positive anaplastic lymphomas and activated at the cell surface by the chaperone heat shock protein 90 to promote cell invasionCancer Res201070176978698720699364
   PubMed Web of Science ®Google Scholar
• ZhangJWangPWuFAberrant expression of the transcriptional factor Twist1 promotes invasiveness in ALK-positive anaplastic large cell lymphomaCell Signal201224485285822155737
   PubMed Web of Science ®Google Scholar
• Gambacorti-PasseriniCMessaCPoglianiEMCrizotinib in anaplastic large-cell lymphomaN Engl J Med2011364877577621345110
   PubMed Web of Science ®Google Scholar
• MosséYPBalisFMLimMSEfficacy of crizotinib in children with relapsed/refractory ALK-driven tumors including anaplastic large cell lymphoma and neuroblastoma: a Children’s Oncology Group phase I consortium studyJ Clin Oncol201230Suppl abstr 9500
   Google Scholar
• National Cancer Institute (NCI)Brentuximab vedotin or crizotinib and combination chemotherapy in treating patients with newly diagnosed stage II–IV anaplastic large cell lymphoma Available from: http://clinicaltrials.gov/ct2/show/NCT01979536 NLM identifier: NCT01979536Accessed February 7, 2014
   Google Scholar
• CoffinCMWattersonJPriestJRDehnerLPExtrapulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor). A clinicopathologic and immunohistochemical study of 84 casesAm J Surg Pathol19951988598727611533
   PubMed Web of Science ®Google Scholar
• CoffinCMHornickJLFletcherCDInflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive casesAm J Surg Pathol200731450952017414097
   PubMed Web of Science ®Google Scholar
• GriffinCAHawkinsALDvorakCHenkleCEllinghamTPerlmanEJRecurrent involvement of 2p23 in inflammatory myofibroblastic tumorsCancer Res199959122776278010383129
   PubMed Web of Science ®Google Scholar
• ChanJKCheukWShimizuMAnaplastic lymphoma kinase expression in inflammatory pseudotumorsAm J Surg Pathol200125676176811395553
   PubMed Web of Science ®Google Scholar
• LawrenceBPerez-AtaydeAHibbardMKTPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumorsAm J Pathol2000157237738410934142
   PubMed Web of Science ®Google Scholar
• CessnaMHZhouHSangerWGExpression of ALK1 and p80 in inflammatory myofibroblastic tumor and its mesenchymal mimics: a study of 135 casesMod Pathol200215993193812218210
   PubMed Web of Science ®Google Scholar
• RaetzEAPerkinsSLCarlsonMASchoolerKPCarrollWLVirshupDMThe nucleophosmin-anaplastic lymphoma kinase fusion protein induces c-Myc expression in pediatric anaplastic large cell lymphomasAm J Pathol2002161387588312213716
   PubMed Web of Science ®Google Scholar
• MoritakeHShimonodanHMarutsukaKKamimuraSKojimaHNunoiHC-MYC rearrangement may induce an aggressive phenotype in anaplastic lymphoma kinase positive anaplastic large cell lymphoma: Identification of a novel fusion gene ALO17/C-MYCAm J Hematol2011861757821080342
   PubMed Web of Science ®Google Scholar
• ButrynskiJED’AdamoDRHornickJLCrizotinib in ALK-rearranged inflammatory myofibroblastic tumorN Engl J Med2010363181727173320979472
   PubMed Web of Science ®Google Scholar
• SodaMChoiYLEnomotoMIdentification of the transforming EML4-ALK fusion gene in non-small-cell lung cancerNature2007448715356156617625570
   PubMed Web of Science ®Google Scholar
• SodaMTakadaSTakeuchiKA mouse model for EML4-ALK-positive lung cancerProc Nat Acad Sci U S A2008105501989319897
   PubMed Web of Science ®Google Scholar
• ShawATYeapBYMino-KenudsonMClinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALKJ Clin Oncol200927264247425319667264
   PubMed Web of Science ®Google Scholar
• KimHRShimHSChungJHDistinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangementCancer2012118372973921720997
   PubMed Web of Science ®Google Scholar
• TakezawaKOkamotoINishioKJannePANakagawaKRole of ERK-BIM and STAT3-survivin signaling pathways in ALK inhibitor-induced apoptosis in EML4-ALK-positive lung cancerClin Cancer Res20111782140214821415216
   PubMed Web of Science ®Google Scholar
• KwakELBangYJCamidgeDRAnaplastic lymphoma kinase inhibition in non-small-cell lung cancerN Engl J Med2010363181693170320979469
   PubMed Web of Science ®Google Scholar
• CamidgeDRBangYJKwakELActivity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 studyLancet Oncol201213101011101922954507
   PubMed Web of Science ®Google Scholar
• ShawATKimDWNakagawaKCrizotinib versus chemotherapy in advanced ALK-positive lung cancerN Engl J Med2013368252385239423724913
   PubMed Web of Science ®Google Scholar
• BergethonKShawATOuSHROS1 rearrangements define a unique molecular class of lung cancersJ Clin Oncol201230886387022215748
   PubMed Web of Science ®Google Scholar
• ChoiYLSodaMYamashitaYEML4-ALK mutations in lung cancer that confer resistance to ALK inhibitorsN Engl J Med2010363181734173920979473
   PubMed Web of Science ®Google Scholar
• DoebeleRCPillingABAisnerDLMechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancerClin Cancer Res20121851472148222235099
   PubMed Web of Science ®Google Scholar
• MoriMUenoYKonagaiSThe selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model miceMol Cancer TheraEpub 1272014
   Web of Science ®Google Scholar
• MarsiljeTHPeiWChenBSynthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2- isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl) pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trialsJ Med Chem201356145675569023742252
   PubMed Web of Science ®Google Scholar
• KatayamaRKhanTMBenesCTherapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALKProc Nat Acad Sci U S A20111081875357540
   PubMed Web of Science ®Google Scholar
• SetoTKiuraKNishioMCH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 studyLancet Oncol201314759059823639470
   PubMed Web of Science ®Google Scholar
• SchulteJHSchulteSHeukampLCTargeted therapy for neuroblastoma: ALK inhibitorsKlin Padiatr2013225630330824166094
   PubMed Web of Science ®Google Scholar
• PughTJMorozovaOAttiyehEFThe genetic landscape of high-risk neuroblastomaNature genetics201345327928423334666
   PubMed Web of Science ®Google Scholar
• Janoueix-LeroseyISchleiermacherGDelattreOMolecular pathogenesis of peripheral neuroblastic tumorsOncogene201029111566157920101209
   PubMed Web of Science ®Google Scholar
• LamantLPulfordKBischofDExpression of the ALK tyrosine kinase gene in neuroblastomaAm J Pathol200015651711172110793082
   PubMed Web of Science ®Google Scholar
• ChenYTakitaJChoiYLOncogenic mutations of ALK kinase in neuroblastomaNature2008455721597197418923524
   PubMed Web of Science ®Google Scholar
• GeorgeRESandaTHannaMActivating mutations in ALK provide a therapeutic target in neuroblastomaNature2008455721597597818923525
   PubMed Web of Science ®Google Scholar
• Janoueix-LeroseyILequinDBrugieresLSomatic and germline activating mutations of the ALK kinase receptor in neuroblastomaNature2008455721596797018923523
   PubMed Web of Science ®Google Scholar
• MosseYPLaudenslagerMLongoLIdentification of ALK as a major familial neuroblastoma predisposition geneNature2008455721593093518724359
   PubMed Web of Science ®Google Scholar
• WangMZhouCSunQALK amplification and protein expression predict inferior prognosis in neuroblastomasExp Mol Pathol201395212413023797004
   PubMed Web of Science ®Google Scholar
• BrodeurGMSeegerRCSchwabMVarmusHEBishopJMAmplification of N-myc in untreated human neuroblastomas correlates with advanced disease stageScience19842244653112111246719137
   PubMed Web of Science ®Google Scholar
• SeegerRCBrodeurGMSatherHAssociation of multiple copies of the N-myc oncogene with rapid progression of neuroblastomasN Engl J Med198531318111111164047115
   PubMed Web of Science ®Google Scholar
• De BrouwerSDe PreterKKumpsCMeta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplificationClin Cancer Res201016174353436220719933
   PubMed Web of Science ®Google Scholar
• ZhuSLeeJSGuoFActivated ALK collaborates with MYCN in neuroblastoma pathogenesisCancer Cell201221336237322439933
   PubMed Web of Science ®Google Scholar
• MosséYPLimMSVossSDSafety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children’s Oncology Group phase 1 consortium studyLancet Oncol201314647248023598171
   PubMed Web of Science ®Google Scholar
• OgnjanovicSLinaberyAMCharbonneauBRossJATrends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975–2005Cancer2009115184218422619536876
   PubMed Web of Science ®Google Scholar
• van GaalJCRoeffenMHFluckeUESimultaneous targeting of insulin-like growth factor-1 receptor and anaplastic lymphoma kinase in embryonal and alveolar rhabdomyosarcoma: a rational choiceEur J Cancer201349163462347023867124
   PubMed Web of Science ®Google Scholar
• DirksWGFahnrichSLisYBeckerEMacLeodRADrexlerHGExpression and functional analysis of the anaplastic lymphoma kinase (ALK) gene in tumor cell linesInt J Cancer20021001495612115586
   PubMed Web of Science ®Google Scholar
• PillayKGovenderDChettyRALK protein expression in rhabdomyosarcomasHistopathology200241546146712405914
   PubMed Web of Science ®Google Scholar
• CoraoDABiegelJACoffinCMALK expression in rhabdomyosarcomas: correlation with histologic subtype and fusion statusPediatr Dev Pathol200912427528318788887
   PubMed Web of Science ®Google Scholar
• YoshidaAShibataTWakaiSAnaplastic lymphoma kinase status in rhabdomyosarcomasMod Pathol201326677278123307059
   PubMed Web of Science ®Google Scholar
• van GaalJCFluckeUERoeffenMHAnaplastic lymphoma kinase aberrations in rhabdomyosarcoma: clinical and prognostic implicationsJ Clin Oncol201230330831522184391
   PubMed Web of Science ®Google Scholar
• KjeldsbergCRPractical Diagnosis of Hematologic DisordersChicago, ILAmerican Society of Clinical Pathology (ASCP)20102
   Google Scholar
• DelsolGLamantLMariameBA new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2; 5 translocationBlood1997895148314909057627
   PubMed Web of Science ®Google Scholar
• BubalaHMaldykJWlodarskaISonta-JakimczykDSzczepanskiTALK-positive diffuse large B-cell lymphomaPediatr Blood Cancer200646564965315852431
   PubMed Web of Science ®Google Scholar
• BeltranBCastilloJSalasRALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literatureJ Hematol Oncol200921119250532
   PubMed Web of Science ®Google Scholar
• ChikatsuNKojimaHSuzukawaKALK+, CD30−, CD20− large B-cell lymphoma containing anaplastic lymphoma kinase (ALK) fused to clathrin heavy chain gene (CLTC)Mod Pathol200316882883212920229
   PubMed Web of Science ®Google Scholar
• De PaepePBaensMvan KriekenHALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphomaBlood200310272638264112750159
   PubMed Web of Science ®Google Scholar
• GascoyneRDLamantLMartin-SuberoJIALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 casesBlood200310272568257312763927
   PubMed Web of Science ®Google Scholar
• GeskSGascoyneRDSchnitzerBALK-positive diffuse large B-cell lymphoma with ALK-Clathrin fusion belongs to the spectrum of pediatric lymphomasLeukemia200519101839184016107887
   PubMed Web of Science ®Google Scholar
• OnciuMBehmFGDowningJRALK-positive plasmablastic B-cell lymphoma with expression of the NPM-ALK fusion transcript: report of 2 casesBlood200310272642264412816858
   PubMed Web of Science ®Google Scholar
• MomoseSTamaruJKishiHHyperactivated STAT3 in ALK-positive diffuse large B-cell lymphoma with clathrin-ALK fusionHum Pathol2009401758218755494
   PubMed Web of Science ®Google Scholar
• Van RoosbroeckKCoolsJDierickxDALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusionsHaematologica201095350951320207848
   PubMed Web of Science ®Google Scholar
• CerchiettiLDamm-WelkCVaterIInhibition of anaplastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-positive human diffuse large B cell lymphomasPloS one201164e1843621494621
   PubMed Web of Science ®Google Scholar
• WassMBehlendorfTSchadlichBCrizotinib in refractory ALK-positive diffuse large B-cell lymphoma: a case report with a short-term responseEur J HaematolEpub 12142013
   Web of Science ®Google Scholar
• PowersCAignerAStoicaGEMcDonnellKWellsteinAPleiotrophin signaling through anaplastic lymphoma kinase is rate-limiting for glioblastoma growthJ Biol Chem200227716141531415811809760
   PubMed Web of Science ®Google Scholar
• HollandECCelestinoJDaiCSchaeferLSawayaREFullerGNCombined activation of Ras and Akt in neural progenitors induces glioblastoma formation in miceNat Genet2000251555710802656
   PubMed Web of Science ®Google Scholar
• Koyama-NasuRHarutaRNasu-NishimuraYThe pleiotrophin-ALK axis is required for tumorigenicity of glioblastoma stem cellsOncogeneEpub 5202013
   Web of Science ®Google Scholar
• NisterMClaesson-WelshLErikssonAHeldinCHWestermarkBDifferential expression of platelet-derived growth factor receptors in human malignant glioma cell linesJ Biol Chem19912662516755167631653246
   PubMed Web of Science ®Google Scholar
• IwaharaTFujimotoJWenDMolecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous systemOncogene19971444394499053841
   PubMed Web of Science ®Google Scholar
• StoicaGEKuoAAignerAIdentification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophinJ Biol Chem200127620167721677911278720
   PubMed Web of Science ®Google Scholar
• MentleinRHeld-FeindtJPleiotrophin, an angiogenic and mitogenic growth factor, is expressed in human gliomasJ Neurochem200283474775312421346
   PubMed Web of Science ®Google Scholar
• StylianouDCAuf der MaurAKodackDPEffect of single-chain antibody targeting of the ligand-binding domain in the anaplastic lymphoma kinase receptorOncogene200928373296330619633684
   PubMed Web of Science ®Google Scholar
• HallbergBPalmerRHMechanistic insight into ALK receptor tyrosine kinase in human cancer biologyNat Rev Cancer2013131068570024060861
   PubMed Web of Science ®Google Scholar
• LinELiLGuanYExon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancersMol Cancer Res2009791466147619737969
   PubMed Web of Science ®Google Scholar
• RobertsonFMPetricoin IiiEFVan LaereSJPresence of anaplastic lymphoma kinase in inflammatory breast cancerSpringerPlus2013249724102046
   PubMedGoogle Scholar
• KrishnamurthySWoodwardWYangWStatus of the anaplastic lymphoma kinase (ALK) gene in inflammatory breast carcinomaSpringerPlus2013240924156086
   PubMedGoogle Scholar
• MuruganAKXingMAnaplastic thyroid cancers harbor novel oncogenic mutations of the ALK geneCancer Res201171134403441121596819
   PubMed Web of Science ®Google Scholar
• NiuHTZhouQMWangFIdentification of anaplastic lymphoma kinase break points and oncogenic mutation profiles in acral/mucosal melanomasPigment Cell Melanoma Res201326564665323751074
   PubMed Web of Science ®Google Scholar
• FleurenEDRoeffenMHLeendersWPExpression and clinical relevance of MET and ALK in Ewing sarcomasInt J Cancer2013133242743623335077
   PubMed Web of Science ®Google Scholar
• LiXQHisaokaMShiDRZhuXZHashimotoHExpression of anaplastic lymphoma kinase in soft tissue tumors: an immunohistochemical and molecular study of 249 casesHum Pathol200435671172115188137
   PubMed Web of Science ®Google Scholar
• ConlonKPBasrurVRollandDFusion peptides from oncogenic chimeric proteins as putative specific biomarkers of cancerMol Cell Proteomics201312102714272323836920
   PubMed Web of Science ®Google Scholar